US Allergy Drugs Industry

• Publication date: February 2010

This report analyzes the US Market for Allergy Drugs in US$ Million by the following types - Prescription Antihistamines, Prescription Corticosteroids, and OTC Allergy Drugs. Annual forecasts are provided for the period 2007 through 2015. The report profiles 109 companies including many key and niche players such as Collegium Pharmaceutical, Inc., McNeil Consumer Healthcare, Meda Pharmaceuticals, Inc., Novartis Consumer Healthcare, Inc., Scherin...

This report analyzes the US Market for Allergy Drugs in US$ Million by the following types - Prescription Antihistamines, Prescription Corticosteroids, and OTC Allergy Drugs. Annual forecasts are provided for the period 2007 through 2015. The report profiles 109 companies including many key and niche players such as Collegium Pharmaceutical, Inc., McNeil Consumer Healthcare, Meda Pharmaceuticals, Inc., Novartis Consumer Healthcare, Inc., Schering-Plough Corp, Sepracor, Inc., and Vicks. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Drug And Medication Industry in the United States

ALLERGY DRUGS MCP-6165
A US MARKET REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3


II. A US MARKET REPORT

1. MARKET REVIEW II-1
Allergy - A Global Perspective II-1
Allergy Prevalence II-1
Allergy - A US Perspective II-1
Allergy Prevalence II-1
Market Overview II-2
Market Outlook II-2
Manufacturers Leverage Opportunity, Announce New Product
Launches II-2
Zyrtec’ Move to OTC Aisles Perks Up OTC Sales II-3
Allergy Patients Turn to Complimentary Medicine II-3
Leading Allergy Products II-4
Table 1: US Allergy Drugs Market - Percentage Share
Breakdown of Antihistamine Products by New Prescriptions for
2007, 2008 and 2009 (includes corresponding Graph/Chart) II-4

Table 2: US Allergy Drugs Market - Percentage Share
Breakdown of Antihistamine + Decongestant Combination
Products by New Prescription for 2007, 2008 and 2009
(includes corresponding Graph/Chart) II-5

Table 3: US Allergy Drugs Market - Percentage Share
Breakdown of Allergy Nasal Spray Products by Total
Prescriptions (in thousands) for 2007 and 2008 (includes
corresponding Graph/Chart) II-5

Table 4: US Allergy Drugs Market - Percentage Share
Breakdown of Allergy Nasal Spray Products by Value Sales for
2007 and 2008 (includes corresponding Graph/Chart) II-6

2. ALLERGY OVERVIEW II-7
Allergy: Definition II-7
Causes/ Factors II-7
Symptoms/ Triggers II-7
Allergic Rhinitis - A Common Allergy II-8
Types of Allergic Rhinitis II-8
Diagnosis of Allergic Rhinitis II-8
Treatment of Allergy II-9
Antihistamines II-9
Antihistamines - List of Select Generic Formulations and
Products II-10
Risks/ Side Effects II-10
Decongestants II-10
Decongestants - List of Select Generic Formulations and
Products II-11
Decongestant + Antihistamine - List of Select Generic
Formulations and Products II-11
Risks/ Side Effects II-11
Corticosteroids II-11
Intranasal Corticosteroids - List of Select Generic
Formulations and Products II-12
Side Effects II-12
Allergy Shots II-12
Other Medicines II-13
Sodium Cromoglycate II-13
Cromolyn Sodium II-13
Leukotriene Modifiers II-13
Glucocorticoids II-13
Leading Allergy Drugs II-13
Claritin II-13
Zyrtec II-14
Benadryl II-14
Pollinex® Quattro II-14
Cortaid II-14
Visine-A II-14
Ocean Sinus Irrigation II-15
Crolom Eye Drops II-15

3. PRODUCT INTRODUCTIONS/ APPROVALS II-16
McNeil Consumer Healthcare Launches Zyrtec for Children II-16
Cobalis Announces Online Launch of Anti-allergy Product II-16
Collegium Pharmaceutical Obtains FDA Approval for AllerNaze II-16
Sanofi-aventis and UCB Win NDA Approval for Xyzal Oral Solution II-17
Sepracor Launches Omnaris Nasal Spray for Seasonal and
Perennial Allergies II-17
Sanofi Aventis Launches Allegra Orally Disintegrating Tablets II-18
Ranbaxy Wins FDA Approval for Generic Zyrtec II-18
Wockhardt Introduces Generic Cetirizine Tablets II-18
Hi-Tech Pharmacal Receives FDA Approval for Fluticasone
Propionate II-18
Boca Pharmacal Wins FDA Approval for Palgic’s Generic Product II-19
Ranbaxy Receives FDA Approval for Cetirizine Hydrochloride
Oral Solution II-19
Perrigo and Teva Receive FDA Approval for Zyrtec-D II-19
Sanofi-aventis Receives FDA Approval for Nasacort AQ® Nasal
Spray II-19
Sanofi-aventis and UCB Introduce Xyzal Anti-allergy Medication II-19
Sanofi-aventis Wins FDA Approval for Allegra® Oral Suspension II-20
Matrixx Launches Zicam Multi-Symptom Cold & Flu Relief Products II-20
Ranbaxy Receives Approval to Market Claritin Reditabs’ Generic II-20
Procter & Gamble Introduces Nyquil D II-20
Leiner to Launch Naproxen Cold & Sinus Private Label Allergy
Products II-20

4. RECENT INDUSTRY ACTIVITY II-21
Merck Announces Business Merger Plan with Schering-Plough II-21
Hi-Tech Pharmacal to Acquire ECR Pharmaceuticals II-21
IBT Laboratories and ViraCor Announce Merger Plan II-21
Lupin Acquires Rights to Collegium’s Intra-nasal Steroid II-22
Cobalis and Melodic Sign Agreement for PreHistin II-22
Patheon Receives Contract to Commercialize Allergy Drugs II-22
Boehringer Ingelheim Signs Agreement for Actimis Acquisition II-23
Perrigo Acquires US Rights to Levocetirizine Tablets II-23
Sciele Pharma Acquires Verus Pharmaceuticals’ Allergy Injection II-23
Sanofi-Aventis and Johns Hopkins University Division Sign
Agreement II-24
Pipex Announces Effective Pharmaceuticals Acquisition II-24
Meda to Take Over American Company, MedPointe II-24
Private Group Proposes to Acquire Majority Interest in Inyx II-24

5. FOCUS ON SELECT PLAYERS II-25
Collegium Pharmaceutical, Inc. II-25
McNeil Consumer Healthcare II-25
Meda Pharmaceuticals, Inc. II-25
Novartis Consumer Healthcare, Inc. II-25
Schering-Plough Corp. II-26
Sepracor, Inc. II-26
Vicks II-27

6. US MARKET PERSPECTIVE II-28
Table 5: US Recent Past, Current & Future Analysis for Allergy
Drugs by Product Segment - Prescription Antihistamines,
Prescription Corticosteroids and OTC Allergy Drugs Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) II-28

Table 6: US Historic Review for Allergy Drugs by Product
Segment - Prescription Antihistamines, Prescription
Corticosteroid and OTC Allergy Drugs Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2001 through 2006 (includes corresponding Graph/Chart) II-28

Table 7: US 15-Year Perspective for Allergy Drugs by Product
Segment - Percentage Breakdown of Annual Value Sales for
Prescription Antihistamines, Prescription Corticosteroids and
OTC Allergy Drugs Markets for Years 2003, 2009 & 2015
(includes corresponding Graph/Chart) II-29


III. REST OF WORLD MARKETS

1. CANADA III-1
Allergy - Overview III-1
Strategic Corporate Developments III-1

2. JAPAN III-3
Allergy - Overview III-3
Product Approvals III-3

3. EUROPE III-4
Allergy - Prevalence III-4
United Kingdom III-4
Allergy - Overview III-4
Russia III-4
Allergy - Overview III-4
Product Launch III-4
Strategic Corporate Developments III-5
Select Players III-5

4. ASIA-PACIFIC III-8
Allergy - Overview III-8
Australia and New Zealand III-8
China III-8
Market Overview III-8
OTC Medications - A Small, But Growing Market III-9
Market Analytics III-9
Table 8: Chinese Recent Past, Current & Future Analysis for
Allergy Drugs - Annual Sales Figures in US$ Million for
Years 2006 through 2015 (includes corresponding Graph/Chart) III-9
India III-10
Market Overview III-10
Malaysia III-10
Allergy - Overview III-10


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 109 (including Divisions/Subsidiaries - 139)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 26
Canada 2
Japan 8
Europe 40
France 4
Germany 7
The United Kingdom 4
Italy 4
Spain 4
Rest of Europe 17
Asia-Pacific (Excluding Japan) 49
Middle-east 13
Africa 1
------------------------------------------